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Alzheimer's disease, an incurable neurodegenerative disease, plagues millions of 
Americans. The scientific community has put Alzheimer's disease at the forefront of 
research and hundreds of organizations and labs are dedicated to providing a broader 
understanding of the disease. This thesis will review the current research on disease 
etiology, diagnostic tools, risk factors and treatment. 
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In 1907, Dr. Alois Alzheimer was presented with a patient who lacked physical 
abnonnalities but had significant problems with memory, thought, learning, and behavior. 
Peculiarly, the symptoms arose at the age of 51 with no hint of problems earlier in life. The 
patient's mental capacities progressively deteriorated, and after 5 years the illness took her life. 
Upon autopsy, Dr. Alzheimer noted significant cerebral atrophy with visible lesions. Tissue 
sampling revealed aggregated neurofibrils in regions where neurons had once been. His 
characterization and detailed, careful notes on the case lead to the discovery of a new 
neurodegenerative disease, named after the physician- Alzheimer's disease (AD) (Lage, 2006). 
Alzheimer's disease now plagues an estimated 5.2 million Americans, with 1 in 8 people 
above age 65 developing the disease. The majority of cases are seen in adults above age 65, 
however roughly 200,000 individuals will develop the disease before age 65. It is projected that 
by the year 20307.7 million Americans will be diagnosed with AD (Alzheimer's Association, 
2008). 
The disease not only robs individuals of their memories, ability to think, and 
independence, but also greatly impacts the lives of the their family and friends. Often the care 
giving responsibilities are filled by family members, who must witness the slow deterioration of 
a loved one's mind and altogether livelihood. Unfortunately, the disease is incurable and current 
treatments only have the ability to postpone disease onset. 
Since the early 1990s there has been a boom in Alzheimer's disease research. With the 
contributions of molecular and genetic research the fonnerly unknown mechanism of 
Alzheimer's is being pieced together. The Human Genome project was monumental in 
understanding the locus and function of genes associated with the disease, such as the presenilins 
(PSI and II), amyloid-B precursor protein (APP), and apolipoprotein E (ApoE). Molecular 
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research of the amyloid-B (AP) plaques, neurofibrillary tangles, and neuronal death has provided 
a platform for future research and a more complete understanding of the neurodegenerative 
disease. 
Sporadic vs. Familial Alzheimer's 
AD can be classified into two categories: dominant familial Alzheimer's disease and non-
dominant (sporadic) Alzheimer's disease. Of the two, sporadic AD is the most common 
accounting for approximately 90-95% of AD cases (Goedert, 2006). Dominant familial AD 
involves an inherited mutated form of AP cleaving and regulating genes (APP, PSI, or PSII). 
Sporadic AD is a result of reduced AP clearance, inheritance of the E4 allele on the 
apolipoprotein E (ApoE) gene, or impaired degradation of Ap. Both forms have a common result 
in the accumulation of an altered form of AP and follow the same disease progression (Selkoe, 
2002). 
Age is the greatest risk factor for developing AD with increasing probability starting after 
age 65. Average age of onset in sporadic AD is 85, however individuals possessing the ApoE E4 
show onset earlier. Dominant familial AD reduces age of onset up to 30 years earlier (LeVine, 
2004). 
Disease Progression 
Alzheimer's hallmark characteristics, AP deposits and tau-containing neurofibrillary 
tangles, target and induce neuronal death within a select group of cells in the cerebral cortex, 
specifically the pyramidal neurons (F elician & Sandson, 1999). The neurons susceptible to 
developing the abnormal protein aggregations are neurons with long, thin axonal projections in 
relation to cell body size, while the short-axoned cells typically escape the lesions (Braak, 2006). 
Another distinguishing characteristic is the degree of myelination- the proj ection neurons are 
3 
unmyelinated or have a single coat, while the short-axon neurons are typically heavily 
myelinated. The suspected underlying mechanism involves the energy requirements of an 
unmyelinated neuron compared to a myelinated neuron. Unmyelinated neurons have higher 
energy demands for impulse conduction and thus have higher oxidative stress imposed on the 
cell compared to myelinated neurons (Braak, 2006). Current research suggests the progression of 
neuronal impairment and death reversely follows the myelination progression. 
Initially, A~ plaques are found within the amygdala and temporal and parietal high-order 
association regions. As the disease progresses, plaques can be found in the meningeal and 
cortical blood vessels with plaque extension into temporal limbic structures (Felician & Sandson, 
1999). Tau protein abnormalities, or neurofibrillary tangles, are also seen with the progression 
of the disease but current histological diagnosis focuses only on A~ plaque distribution (Felician 
& Sandson, 1999). 
AD progresses in 6 stages (1-VI), Stage I is limited to the cortical cells of the superficial 
transentorhinal region and as the lesions in the transentorhinal region become more severe the 
disease progresses into Stage II . Stage II also sees progression of lesions extending to the 
hippocampus. As lesions worsen AD progresses into Stage III where the disease extends to the 
neocortex of the ocipitotemporal region. During Stage IV, the already present lesions become 
more pronounced and the high order association centers of the neocortex become involved along 
with the superior temporal gyrus. Stage V and VI see further progression of lesions into frontal 
and occipital neocortex (Braak, 2006). 
Amyloid Cascade Hypothesis 
The mechanism of AD pathology is currently unknown, however the main consensus of 
the scientific community is that the A~ protein is the key player in the disease progression. In 
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the early 1990s, John Hardy, along with other contributors, proposed the "Amyloid Cascade 
Hypothesis." This hypothesis proposes that mutations in the A~ cleaving genes cause the 
deposition of A~ plaques, which then results in neuronal injury and subsequent death (Hardy & 
Selkoe, 2002; Hardy, 2006; Felician & Sandson, 1999). The hypothesis has received criticism in 
recent years, however the nature of a hypothesis allows it to be flexible, and as research builds 
more evidence and support, the hypothesis changes. 
Another argument in AD research concerns the tau protein and its role in the amyloid 
cascade hypothesis. Recent evidence shows that the neurofibrillary tangles (containing tau) are 
not able to induce the A~ plaque formation seen in AD, even at neurotoxic concentrations. 
Furthermore, neurofibrillary tangles are seen after the deposition of A~, which is supported by 
animal model studies (Hardy & Selkoe, 2002; LeVine, 2004). In familial AD, the genes 
controlling and influencing A~ cleavage are mutated and can accelerate the age of disease onset 
giving more support to the amyloid hypothesis. In addition, clinical trials of A~ immunization 
treatment showed cognitive stabilization and in some cases improvement (LeVine, 2004). 
Similar to other neurodegenerative diseases like Parkinson's or Huntington's disease, the 
problem is often accumulation and reduced clearance of a misfolded protein, much like the A~ 
protein seen in Alzheimer's (LeVine, 2004). All of which provide further support for the 
amyloid cascade hypothesis. 
Abnormal Filaments 
A~ plaques, neurofibrillary tangles, neuronal death and lesions are hallmark 
characteristics of AD. They are present at various concentrations in every AD brain. The 
abnormal filaments, A~ and neurofibrillary tangles, are the suspected culprits of neuronal death 
and synaptic loss, however their toxic mechanisms are still under debate. 
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AI3 is a product of proteolytic cleavage of the large amyloid precursor protein (APP). 
APP is a transmembrane protein and has various isoforms with lengths ranging from 590-680 
amino acids (Carter & Lippa, 2001). The 695- amino acid form is predominantly found in 
neuronal cells, while other isoforms can be found in neuronal and non-neuronal cells (Felician & 
Sandson, 1999). Its function is unknown, but it is suspected to playa role in neurite extension, 
interneuronal signaling, cell-cell communication and neuroprotection (Carter & Lippa, 2001; 
Macconi et.al, 2001). Recent research suggests APP is a vesicle receptor for kinesin, meaning it 
is involved in intracellular trafficking. Deregulation of intracellular trafficking may playa role 
in the AD pathology (Mac coni et.al, 2001). 
APP is cleaved to produce AI3 peptides composed of 39-43 amino acids. Three proteases 
are responsible for APP cleavage, which are a, 13, and y- secretase. a-secretase cleaves within 
the AI3 domain, leaving the carboxy and amino terminals of AI3 within APP (Carter & Lippa, 
2001; Macconi et.al, 2001). 13- secretase, an alternative cleavage pathway, cleaves at the amino 
terminal generating a peptide containing AI3. The final cleavage pathway includes y- secretase, 
which cleaves AI3 at the carboxy terminal. The generation of the full length AI3 is a result of 13-
cleavage followed by y-cleavage (Carter & Lippa, 2001; Goedert, 2006; Felician & Sandson, 
1999). y-cleavage results in the variation between 40-42 amino acids of the AI3 peptide (Carter 
& Lippa, 2001). 
These variants differ by number of amino acids at the C-terminus. This area determines the 
solubility of the peptide (Felician & Sandson, 1999). The AI3 variant, containing 40 amino acids, 
is soluble and is found in higher concentrations within neuritic plaques of mature dense AI3 
plaques of AD patients (Felician & Sandson, 1999; Carter & Lippa, 2001). The A1342 compared 
to the A1340 variant is the more neurotoxic of the two and has a higher likelihood of forming 
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plaques. A~40 appears to be the main component of the insoluble fibrils and the soluble 
oligomers associated with A~ plaques (LeVine, 2004). In cognitively normal patients, A~40 is 
seen in higher concentrations than A~42 (Carter & Lippa, 2001). 
Most A~ is produced within the cell and remains in the intracellular compartment with a 
small amount destined for extracellular secretion (LeVine, 2004). The A~42 is produced in the 
endoplasmic reticulum and mostly remains intracellularly, while the A~40 is produced in the 
Golgi apparatus for exocytotic secretion (LeVine, 2004). While it is thought that the A~ seen in 
extracellular plaques is produced within the cell, the hypothesis currently lacks sufficient support 
(Carter & Lippa, 2001). The A~ secreted from the neuron is in the form of monomers and 
dimers and when it reaches the interstitial fluid it polymerizes into soluble A~ oligomers, which 
can be cleared (Kumar-Singh, 2008). In AD, the oligomers aggregate into high molecular 
weight proto fibrils to create diffuse plaques and eventually create the dense plaques 
characteristic of AD (Kumar-Singh, 2008). 
A~ is normally present in the cerebrospinal fluid (CSF); the brain synthesizes the protein 
which is then deposited into the CSF to circulate through the central nervous system (LeVine, 
2004). Neuronal cells and non-neuronal cells produce A~ in normal homeostatic states and its 
production is mediated by the influx and efflux of the peptide (Levine, 2004). The normal rate 
indicates that A~ is rapidly produced and cleared from the CNS; however, the A~ accumulation 
in the AD brain is 100-200 times that seen in control brains (Bateman et.al, 2006). In familial 
AD, there is an over-production of total A~ or A~42' but in sporadic AD (99% of the cases) it is 
unknown whether the A~ plaque accumulation is a result of overproduction of A~ or decreased 
clearance (Bateman et.al, 2006). A~ is degraded by macrophages, proteases, and the cerebral 
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blood vessels. The metallopeptidases responsible for breaking down A~ include neprilysn, 
insulin-degrading enzyme, endothelial-converting enzyme-1 and -2, and metalloproteinase-2 and 
-9 (Kumar-Singh, 2008). A~ is also cleared via low-density lipoprotein receptor-related protiein-
1 (LRP-1) across the blood brain barrier, where the LRP-1 receptors are influenced by ApoE 
(Kumar-Singh, 2008). 
The tau molecule plays another important role in the suspected mechanism of AD 
pathology. The neurofirbillary tangles seen within neurons were found to be composed of paired 
helical filaments of the tau protein. Tau is a family of proteins that is associated with 
microtubule stabilization of the intraceullular cytoskeleton ofaxons and neurite formation (Chun 
& Johnson, 2007). While is can be expressed in other cells (glial cells and oligodendrocytes), it 
is predominantly expressed in neurons. Recent evidence shows that tau may also be involved in 
vesicle transport and axonal polarity (Chun & Johnson, 2007). 
Normally tau is highly soluble and remains in an unfolded conformation with little 
secondary structure. In AD, tau becomes compacted into fibrils, which is facilitated by 
truncation at the carboxy terminal and selective amino acid phosphorylation (Chun & Johnson, 
2007). The hyperphosphorylation of tau promotes the self-assembly of the protein into paired 
helical filaments, a hallmark characteristic seen in AD brains (Chun & Johnson, 2007; Macconi 
et.al. 2001). Normal phosphorylation of tau is the mechanism thought to produce the stabilizing 
effect on axon cytoskeletal structures. The inability of tau to interact with microtubules is 
suspected to induce the toxic internal state leading to neurodegeneration (Goedert, 2006). 
The neurofibrillary tangles characterisitic of AD are found primarily in the neurons of the 
hippocampus, entorhinal cortex, and amygdala (Macconi et.al. 2001). The neuroprotective 
effects of tau are dependent on protein kinases, such as cyclin-dependent kinase 5 (Cdk5) and 
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glycogen synthase kinase-beta (GSK3P), which prevent the hyperphosyphorlyation oftau and 
the subsequent neuronal death associated with AP toxicity (Macconi et. aI, 2001). One study 
suggests that hyperphosphorylation is a reversible process, but the self-aggregation of tau into 
tangles is permanent. Once the tangles appear the cell can no longer enter the cell-cycle and 
undergo neurogenesis (Schindowski et.al, 2008). AP deposits in the interstitial fluid are thought 
to promote the degradation of the neurofibrillary machinery, however the process is not 
completely understood at this time. 
Mechanism of Neuronal Death 
At the time, there is no universally accepted mechanism of neuronal death in AD. The 
amyloid hypothesis, discussed earlier, suggests that AP has a toxic effect on neuronal dendrites 
and synapses. The support for this hypothesis comes from studies showing AP to be neurotoxic, 
however, there is little support for the presence of Ap alone causing direct neuronal death 
(LeVine, 2004). 
One other suspected mechanism, is the production of AP40 and AP42 within the neuron 
produces toxic effects intracellulary by interfering with neurona1 function, specifically synaptic 
plasticity (Venkitaramani et.al, 2007). Intreneuronal AP interferes with glutamate receptors, 
which are critical in synaptic plasticity and memory explaining the cognitive impairment seen in 
AD patients. This mechanism is supported by studies of familial AD where the genes 
responsible for cleaving APP (presenilins) are mutated. These genes are not only responsible for 
cleaving APP but also other proteins causing the accumulation of AP and other possibly 
neurotoxic proteins (LeVine, 2004). The early-onset of AD in the familial type suggests that AP 
and these other proteins are involved in the death process. 
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Another hypothesis involves the deregulation of Calcium (Ca2+) and the increased 
concentrations intracellularly. Nomlally, Ca2+ regulation is under strict control, but research has 
shown the addition of AP to in vitro cells disrupts Ca2+ signaling and produces an influx of Ca2+. 
This influx of Ca2+ may playa role in activating cellular enzymes, apoptosis, and cause 
modification to the cytoskeleton (Bojarski et.al, 2008). Presence of AP may also lead to lipid 
oxidation of the semi-permeable bilayer of the cell causing conformational changes of ion 
channels allowing the influx of Ca2+. The influx ofCa2+ then increases the generation of AP, 
exacerbating the original problem in a positive feedback loop. 
It is known that AP induces cellular apoptosis in vitro and enhances cellular death 
through oxidative stress. The typical apoptoic pathway, including membrane blebbing, 
chromatin fragmentation, and capsase activation can be seen in neuronal cultures (Eksyyan & 
AW,2004). The oxidative stress as a result of AP exposure is still under investigation. 
Oxidative stress is a direct result of oxidants overpowering antioxidant molecule abilities. In AD 
there is an overproduction of reactive oxygen and nitrogen species, such as nitric oxide, 
superoxide, hydrogen perioxide and perioxynitrite (Maccioni et.al, 2001; Hayashi, 2006). The 
presence of these oxidants causes cellular damage and can signal apoptosis. 
The AP peptides and oligomers, along with oxidative stress, triggers an inflammatory 
response by the brain's immune system. Studies show increased cytokine concentrations in AD 
patients compared to age-matched control patients (Felician & Sandson, 1999). The cytokines 
and neuroimmune modulators of the brain are thought to playa role in both neuroprotection and 
neurodegeneration (Rojo et.al, 2008). Interleukin-1 (IL-1) is suspected to enhance 
neurodegeneration by upregulating tau hyperphosphorylation and by inducing the production of 
nitric oxide, an oxidant, within neurons (Rojo et.al, 2008). Interleukin-6 (IL-6) another cytokine 
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released by activated glial cells also plays a role in neuroinflammation and cognitive impairment. 
Interestingly, IL-3 plays a role in neuroprotection, showing that the cytokines are complex and 
have various involvements in AD. Along with cytokines, neuroinhibitory molecules 
(semaphorin 3A, collapsin-response mediator protein 2, etc.) are suspected to playa role 
downstream of initial AP deposition to result in neuronal damage (Lamer & Keynes, 2006). 
The large-scale neuronal damage and death are responsible for the cognitive impairments 
seen in AD. The degeneration process begins in the entorhinal cortex and extends to the 
hippocampus, dentate gyrus, and is followed by neuronal loss of the neocortex and the nucleus 
basalis of Meynert (Masliah et aI, 2008). Neuronal death in these crucial areas leads to the 
memory loss, attention deficits, mood changes, logic impairments and confusion experienced in 
an AD patient. The underlying mechanism is loss of functioning synapses resulting from the 
toxic AP plaques, tau-containing neurofibrillary tangles, oxidative stress, and cytokines of 
neuroimmune cells (Mashliah et.al, 2008). 
Genetics of Alzheimer's Disease 
AD is a genetic disease with known linkages to mutated genes. Mutations in the APP 
processing gene, presenilin-l and -2, as well as the ApoE gene are linked to familial (early-
onset) AD. Currently all of the genes associated with AD result in improper processing of APP 
causing the accumulation of AP peptides (Tan don et.al, 2000). The APP gene is located on 
chromosome 21, which also the gene associated with Down's Syndrome. People with Down's 
Syndrome eventually present Alzheimer's-like symptoms, which is correlated to the additional 
copy of APP in their genome. 
Mutations on the long arm of chromosome 14 have been linked to a mutated form of 
presnilin-I (PSI), and mutations on chromosome I have been linked to presenilin-2 (PS2) 
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dysfunction (F elician & Sandson, 1999). These two genes account for 50-70% of familial 
dominant AD cases and result in early-onset of the disease (Felician & Sandson, 1999). The 
physiological role of these proteins is unknown, but it is thought they are involved in 
intracellular trafficking and AP production (Felician & Sandson, 1999). Evidence shows that the 
presnilins influence the y-secretase cleavage pathway and promotes the production of AP 
(Tandon et.al, 2000). Knock-out mice, lacking the presnilin complex, show decreased AP 
production due to only u- and p-secretase activity. 
The gene encoding ApoE lies on chromosome 19, and mutations of this gene are 
associated with increased susceptibility of developing sporadic AD or late-onset familial AD. 
The gene has 4 alleles, with the 84 allele being the most lethal, such that two copies of the allele 
are associated with earlier disease onset (Hirono et.al, 2003). Inheritance of the ApoE 84 allele 
can result in a 20-year shift in disease onset (Tandon et.al, 2000). ApoE 84 alters the processing 
of APP, binds with AP, and competes with AP peptide for clearance through the LRP-l (Tandon 
et.al, 2000). 
Diagnosis 
AD diagnosis typically begins with the primary care physician recognizing slight 
dementia and calling for further cognitive functioning tests. Unfortunately, AD is recognized 
when the symptoms begin to interfere with the individual's everyday life, which are signals of 
moderate to severe AD (Grober et.al, 2008). Current diagnostic tools include global cognitive 
function screening tests and brain imaging. In order to c1inical1y diagnosis dementia there must 
be cognitive impairment in memory, so the primary diagnostic tools measure memory and 
similar functions (Grober et.al, 2008). 
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Zaven Khachaturian, an AD researcher, describes four categories of assessment tools 
used in diagnosing dementia including mental status exams, global measures of dementia 
severity, behavioral scales, and cognitive assessment batteries (Khachaturian, 2006). Mental 
status exams include Mini-mental Status Exam and Short Blessed Test, while the global 
measures of dementia severity use tests such as the Global Deterioration Scale and CAMDEX. 
Behavioral scales include the Geriatric Depression Scale to rule out dementia as a result of 
depression; and the cognitive assessment batteries include the Alzheimer Disease Assessment 
Scale (Khachaturian, 2006). 
The Mini-mental State Examination (MMSE), a mental status exam, is the most 
commonly used tool in assessing cognitive functioning in AD patients (Apostolova et.al, 2006). 
The MMSE tests for cognitive decline through testing patients on memory, language, short-term 
memory, orientation, thought construction and attention (Apostolova et.al, 2006; Grober et.al, 
2008). Interestingly, Apostolova and fellow researchers have been able to correlate MMSE 
score decline with cortical atrophy in the temporal, parietal, and frontal association cortexes, 
with respect to gray matter density (Apostolova et.al, 2006). 
Early AD is difficult to diagnosis due to the nature of disease in that memory and 
cognitive impairments arise later in disease progression- it is estimated the neurodegeneration 
begins 20-30 years before the appearance of the clinical symptoms (Goedert, 2006). One aim of 
current research is to develop diagnostic tools that will recognize AD at its earlier stages. Brain 
imaging research is working in that direction so that AD can be diagnosed and treated earlier in 
the disease progression. The National Institute of Aging established the Alzheimer's Disease 
Neuroimaging Initiative (ADNI) promotes the discovery of new diagnostic tools and to improve 
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the current imaging methods (ThaI et.al, 2006). There are numerous types of brain imaging 
techniques, and some are more useful than others. 
Positron emission topography (PET) displays glucose uptake through imaging regions of 
the brain that are actively taking up radio-labeled 2-deoxyglucose. Most PET scans of AD 
patients show a decreased glucose uptake in the parieto-temporal association cortex and the 
cingulate gyrus compared to control patients (Wu & Small, 2006). However, the PET scan does 
not show the entorhinal cortex, the region holding the hippocampus. 
Another method of imaging is through visualizing cerebral blood flow by using PET, 
single photon emission computed tomography (SPECT), and magnetic resonance imaging (MRI) 
(Wu & Small, 2006). The cerebral blood flow imaging methods typically show decreased 
perfusion in the temporal and parietal cortex areas and also reduced blood flow to the entorhinal 
cortex (Wu & Small 2006). The MRl imaging technique shows the best spatial resolution in that 
it is able to visualize the entorhinal cortex, the region suspected to undergo neuronal death in 
early AD. 
Conclusion 
As more individuals enter late adulthood their risk of developing AD significantly 
increases. By 2030 an estimated 7.7 million Americans will be diagnosed with this disease. It is 
necessary that we develop more effective diagnosing tools so that AD can be found in its earliest 
stages. A better understanding of the underlying mechanism in disease progression should be at 
the forefront of AD research. With a better understanding of the molecular and structural 
abnormalities seen in AD we can work towards developing better treatment and disease 
prevention. 
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Currently, AD treatment is palliative with no cure. The drugs prescribed to AD patients 
temporarily delay the onset of more severe symptoms. Cholinesterase inhibitors are frequently 
prescribed; they slow the breakdown of acetylcholine, a neurotransmitter necessary for memory 
formation (Nordberg, 2006). Memantine, a relatively new drug used to treat moderate to severe 
AD, serves as an NMDA receptor antagonist by blocking excess glutamate in the synapse from 
disturbing signal transmission (Reisburg et.al, 2003). Antioxidants may also be administered to 
reduce the oxidative stress on hippocampal neurons, however there is limited evidence showing 
antioxidants to have a significant effect on delaying AD symptoms (Morris et.al, 2006). 
Neurotrophic factors, such as nerve growth factor, brain-derived neurotropic factor, and 
fibroblast growth factor-2 have been identified as a future direction of AD treatment. 
Specifically, nerve growth factor has been shown to prevent the death of basal forebrain 
cholinergic neurons in promising animal studies (Tuszynski, 2007). 
While AD cannot be prevented, a few delaying factors have been identified. Aside from 
age and genetic risk factors, education, leisure activities and occupation are seen as the top three 
delaying factors. Low educational levels are directly related to a higher risk of developing AD. 
It is believed education increases cognitive reserve by increasing synaptic connections (Gatz 
et.al, 2006). Cognitively stimulating leisure activities have been shown to lower the risk of AD 
and possibly protect against dementia. Activities such as traveling, reading, playing musical 
instruments, board games, and dancing were included in what is thought to be cognitively 
stimulating. Finally, occupations with high mental demand and low physical demand are at a 
lower risk for developing AD (Gatz et.al, 2006). 
The future of AD largely depends on the scientific research and funding of organizations 
and labs dedicated to unfolding the basis of this disease and to the development of better 
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diagnostic methods and more effective treatments. In the last 20 years, AD has come to the 
forefront of aging and neurodegenerative research and the information presented has been 
monumental in further understanding the disease. It is my hope that the next 20 years produce an 
even broader grasp of the disease, so that we can alleviate the suffering of people with the 
disease and those closely affected by it. 
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